employees working to find solutions
patients treated with our products to date
Patient Resources
Review information, resources and connections to help you get the most out of your care.
Our Products
Monjuvi® (tafasitamab-cxix)
Diffuse large B-cell lymphoma, follicular lymphoma
Jakafi® (ruxolitinib)
Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host disease
Jakafi XR™ (ruxolitinib XR)
Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host disease
Niktimvo™ (axatilimab-csfr)
Co-commercialized with Syndax
Chronic graft-versus-host disease
Pemazyre® (pemigatinib)
Cholangiocarcinoma, myeloid/lymphoid neoplasms with FGFR1 rearrangement
Zynyz® (retifanlimab-dlwr)
Merkel cell carcinoma, squamous cell carcinoma of the anal canal
Iclusig® (ponatinib)
Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia
Minjuvi® (tafasitamab)
Diffuse large B-cell lymphoma, follicular lymphoma
Pemazyre® (pemigatinib)
Cholangiocarcinoma, myeloid/lymphoid neoplasms with FGFR1 rearrangement
Zynyz® (retifanlimab)
Merkel cell carcinoma, squamous cell carcinoma of the anal canal
As of November 11, 2026